155 related articles for article (PubMed ID: 14707960)
21. Three-month, randomized, parallel-group comparison of brimonidine-timolol versus dorzolamide-timolol fixed-combination therapy.
Nixon DR; Yan DB; Chartrand JP; Piemontesi RL; Simonyi S; Hollander DA
Curr Med Res Opin; 2009 Jul; 25(7):1645-53. PubMed ID: 19476406
[TBL] [Abstract][Full Text] [Related]
22. Hypotension and bradycardia in infants after the use of topical brimonidine and beta-blockers.
Mungan NK; Wilson TW; Nischal KK; Koren G; Levin AV
J AAPOS; 2003 Feb; 7(1):69-70. PubMed ID: 12690374
[TBL] [Abstract][Full Text] [Related]
23. An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure.
Hatanaka M; Grigera DE; Barbosa WL; Jordao M; Susanna R
J Glaucoma; 2008 Dec; 17(8):674-9. PubMed ID: 19092465
[TBL] [Abstract][Full Text] [Related]
24. Side effects of glaucoma medications.
Detry-Morel M
Bull Soc Belge Ophtalmol; 2006; (299):27-40. PubMed ID: 16681086
[TBL] [Abstract][Full Text] [Related]
25. Effects of topical clonidine versus brimonidine on choroidal blood flow and intraocular pressure during squatting.
Weigert G; Resch H; Garhofer G; Fuchsjäger-Mayrl G; Schmetterer L
Invest Ophthalmol Vis Sci; 2007 Sep; 48(9):4220-5. PubMed ID: 17724210
[TBL] [Abstract][Full Text] [Related]
26. The safety and intraocular pressure-lowering efficacy of brimonidine tartrate 0.15% preserved with polyquaternium-1.
Whitson JT; Ochsner KI; Moster MR; Sullivan EK; Andrew RM; Silver LH; Wells DT; James JE; Bosworth CF; Dickerson JE; Landry TA; Bergamini MV;
Ophthalmology; 2006 Aug; 113(8):1333-9. PubMed ID: 16877072
[TBL] [Abstract][Full Text] [Related]
27. Twenty-four-hour efficacy of the brimonidine/timolol fixed combination versus therapy with the unfixed components.
Konstas AG; Katsimpris IE; Kaltsos K; Georgiadou I; Kordelou A; Nelson LA; Stewart WC
Eye (Lond); 2008 Nov; 22(11):1391-7. PubMed ID: 17571086
[TBL] [Abstract][Full Text] [Related]
28. Ophthalmic drops causing coma in an infant.
Berlin RJ; Lee UT; Samples JR; Rich LF; Tang-Liu DD; Sing KA; Steiner RD
J Pediatr; 2001 Mar; 138(3):441-3. PubMed ID: 11241061
[TBL] [Abstract][Full Text] [Related]
29. Brimonidine-induced anterior uveitis and conjunctivitis: clinical and histologic features.
Nguyen EV; Azar D; Papalkar D; McCluskey P
J Glaucoma; 2008; 17(1):40-2. PubMed ID: 18303383
[TBL] [Abstract][Full Text] [Related]
30. Systemic adverse effects of topical treatment with brimonidine in an infant with secondary glaucoma.
Korsch E; Grote A; Seybold M; Soditt V
Eur J Pediatr; 1999 Aug; 158(8):685. PubMed ID: 10445353
[No Abstract] [Full Text] [Related]
31. Efficacy and safety of brimonidine, dorzolamide and latanoprost as adjunctive therapy in primary open angle glaucoma.
Sodhi PK; Pandey RM; Ratan SK
Int J Clin Pract; 2003 Dec; 57(10):875-8. PubMed ID: 14712889
[TBL] [Abstract][Full Text] [Related]
32. Prophylaxis for second eye involvement in leber hereditary optic neuropathy: an open-labeled, nonrandomized multicenter trial of topical brimonidine purite.
Newman NJ; Biousse V; David R; Bhatti MT; Hamilton SR; Farris BK; Lesser RL; Newman SA; Turbin RE; Chen K; Keaney RP
Am J Ophthalmol; 2005 Sep; 140(3):407-15. PubMed ID: 16083844
[TBL] [Abstract][Full Text] [Related]
33. Allergic reactions to brimonidine in patients treated for glaucoma.
Blondeau P; Rousseau JA
Can J Ophthalmol; 2002 Feb; 37(1):21-6. PubMed ID: 11865954
[TBL] [Abstract][Full Text] [Related]
34. [Depression of respiration via toxic effects on the central nervous system following use of topical brimonidine in an infant with congenital glaucoma].
Heimann K; Peschgens T; Merz U; Hoernchen H; Wenzl T
Ophthalmologe; 2007 Jun; 104(6):505-7. PubMed ID: 17334744
[TBL] [Abstract][Full Text] [Related]
35. Update in glaucoma: the new pharmacotherapies. Brimonidine versus apraclonidine.
Crichton AC
Can J Ophthalmol; 1998 Aug; 33(5):254-5; discussion 257-8. PubMed ID: 9740952
[No Abstract] [Full Text] [Related]
36. Can ophthalmic drops cause central nervous system depression and cardiogenic shock in infants?
Kiryazov K; Stefova M; Iotova V
Pediatr Emerg Care; 2013 Nov; 29(11):1207-9. PubMed ID: 24196091
[TBL] [Abstract][Full Text] [Related]
37. Costs and persistence of brimonidine versus brinzolamide in everyday glaucoma care: an analysis conducted on the UK General Practitioner Research Database.
Lafuma A; Laurendeau C; Berdeaux G
J Med Econ; 2008; 11(3):485-97. PubMed ID: 19450100
[TBL] [Abstract][Full Text] [Related]
38. Clinical effects of brimonidine ophthalmic drops ingestion in 52 dogs.
Welch SL; Richardson JA
Vet Hum Toxicol; 2002 Feb; 44(1):34-5. PubMed ID: 11824775
[TBL] [Abstract][Full Text] [Related]
39. Effect of brimonidine tartrate 0.2% ophthalmic solution on pupil size.
Kesler A; Shemesh G; Rothkoff L; Lazar M
J Cataract Refract Surg; 2004 Aug; 30(8):1707-10. PubMed ID: 15313294
[TBL] [Abstract][Full Text] [Related]
40. [Selective α2-agonists in the treatment of glaucoma: pharmacology, efficacy and safety].
Kurysheva NI
Vestn Oftalmol; 2019; 135(2):144-150. PubMed ID: 31215546
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
